For assistance, contact your pharmacy representative: ____________ Phone: ____________ **(For providers only)**

PLEASE CONSIDER SENDING YOUR PRESCRIPTION ELECTRONICALLY. ALL OF OUR PHARMACY LOCATIONS ACCEPT ELECTRONIC PRESCRIPTIONS.

Note: This form is intended for prescriber use only, if faxed, the fax must come from MD office or hospital **(may not be faxed by patient)**.

Walgreens | allianceRx Walgreens + PRIME

Crohn's Disease/Ulcerative Colitis
Prescription/Pharmacy Intake Form

☐Central Pharmacy: ____________
☐Retail/Community Pharmacy Fax: ____________ Pharmacy Phone: ____________
Date Needed: ____________ **Ship To:** ☐Prescriber's Office ☐Patient's Home ☐Other: ____________

PATIENT INFORMATION

Patient name: ____________ DOB: ____________ ☐Male ☐Female
Address: ____________ City: ____________ State: ______ Zip code: ____________
Phone # (Daytime): ____________ Phone # (Evening): ____________
E-mail Address: ____________ Case Manager: ____________
Insurance provider **(Please include copy of front and back of card)**: ____________
ID #: ____________ Policy/Group #: ____________ Phone #: ____________ ☐Patient is eligible for Medicare
Name of Insured: ____________ Employer: ____________
Relationship to Patient: ☐Self ☐Other: ____________ Prescription Card: ☐Yes ☐No Carrier: ____________ Policy/Group #: ____________
Will there be access to anaphylactic medications and oxygen at the administration site? ____________

CLINICAL ASSESSMENT – Please complete ALL sections to avoid delays in filling prescription

☐Patient is new to therapy ☐Patient is currently on therapy Start date: ____________ ☐Physician Provides Injection Training Injection/Infusion Date: ____________
Primary Diagnosis Code and Condition (ICD-10): ____________ Other Diagnosis/Conditions: ____________
Date of Diagnosis: ____________ Current Weight: ____________ Date: ____________ TB Test Results & Date: ____________
☐New Therapy Induction ☐Therapy Change ☐Therapy Continuation | Weeks Completed ☐0 ☐2 ☐4 ☐6 | Stop Date: ____________
☐Unresponsive to Conventional Treatment ☐Other Therapies Tried & Failed (Please List): ____________
Allergies: ____________

Medication	Dose/Directions/Frequency	Quantity	Refills
Cimzia (certolizumab pegol) ☐Starter Kit 6x200mg prefilled syringes			
☐Cimzia 2x200mg vials ☐Cimzia 2x200mg prefilled syringes			
Entyvio (vedolizumab) ☐300mg vial			
Humira (adalimumab) ☐Humira CD/UC/HS Starter Kit 6x40mg pens ☐Humira Pediatric Crohn's Starter Kit 3x40mg prefilled syringes ☐Humira Pediatric Crohn's Starter Kit 6x40mg prefilled syringes			
☐40mg/0.8ml pens ☐40mg/0.8ml prefilled syringes ☐20mg/0.4ml pediatric prefilled syringes			
Humira citrate free (adalimumab) ☐Humira citrate free CD/UC/HS Starter Kit 3x80mg/0.8ml Pens ☐Humira citrate free Pediatric Crohn's Starter Kit 3x80mg/0.8ml PFS ☐Humira citrate free Pediatric Crohn's Starter 1x80mg/0.8ml, 1x40mg/0.4ml PFS			
☐40mg/0.4ml citrate free pens ☐40mg/0.4ml citrate free prefilled syringes ☐20mg/0.2ml citrate free pediatric prefilled syringes			
Inflectra (infliximab-dyyb) ☐100mg vial			
Remicade (infliximab) ☐100mg vial			
Renflexis (infliximab-abda) ☐100mg vial			
Simponi (golimumab) ☐100mg SmartJect auto injector ☐100mg prefilled syringe ☐Other: ____________			
Stelara (ustekinumab) ☐Induction: 130mg/26ml vial			
☐Maintenance: 90mg prefilled syringe ☐Other:			
Tysabri ☐Tysabri – Contact Touch (Biogen Idec) at 1-800-456-2255 or at 1-800-840-1278 (fax)			
Xeljanz (tofacitinib) ☐5mg tablet ☐10mg tablet			
Other: ____________			

I authorize, by my signature below, the dispensing of appropriate needles and syringes, in a sufficient quantity, required for the administration of injectable products by patient or caregiver. Authorization for supplies runs concurrently with the number of refills or time frame specified for the drug.

PRESCRIBER INFORMATION

Prescriber's name: ____________ Practice/facility: ____________
Address: ____________ City: ____________ State: ______ Zip code: ____________
Office contact: ____________ Phone: ____________ Fax: ____________
Email: ____________ Best time to call: ____________ Preferred method of contact: ☐Email ☐Phone ☐Fax
State license #: ____________ DEA #: ____________ NPI #: ____________ Medicaid UPIN #: ____________
In order for a brand name product to be dispensed, the prescriber must handwrite **"Brand Necessary"** or **"Brand Medically Necessary"** or your state specific required language after their signature.
I certify that the above therapy is medically necessary and that the information above is accurate to the best of my knowledge. Prescriber's signature required on one of the lines below.

____________ Dispense as written ____________ Substitution permitted ____________ Date

The prescriber is to comply with his/her state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

The document(s) accompanying this transmission may contain confidential health information that is legally protected. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless permitted or required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.
Drug names are the property of their respective owners.
©2018 All rights reserved. 101818